Harmony Biosciences Holdings, Inc. logo

Harmony Biosciences Holdings, Inc. (HRMY) Financials

NASDAQ NASDAQ:HRMY

Market Cap

2.21B

Total Revenue

437.86M

Gross Profit

354.37M

Operating Income

120.19M

Net Income

181.47M

Metric20182019202020212022
--5,995,000159,742,000305,440,000437,855,000
--1,577,00027,738,00055,518,00083,481,000
--4,418,000132,004,000249,922,000354,374,000
12,372,00069,595,00019,448,00030,367,00070,886,000
16,861,00044,318,00055,824,00068,118,00079,285,000
12,206,00036,409,00039,746,00063,909,00084,017,000
29,067,00080,727,00095,570,000132,027,000163,302,000
41,439,000150,322,000115,018,000162,394,000234,188,000
-41,439,000-145,904,0003,678,00068,704,000120,186,000
1,541,000-6,073,000-40,622,000-31,276,000-15,500,000
-41,255,000-142,694,00013,915,00087,544,000120,355,000
184,0003,210,00010,237,00018,840,000169,000
----------
----28,220,00023,970,00015,669,000
-39,898,000-151,977,000-36,944,00037,428,000104,686,000
1,541,0006,073,00014,912,0002,831,000-76,782,000
-39,898,000-158,050,000-51,856,00034,597,000181,468,000
-0.81-2.86-2.010.63.14
-0.81-2.86-2.010.583.14
49,239,21155,278,57425,772,41957,531,54059,173,121
49,239,21155,278,57425,772,41959,205,21361,097,045
41,439,000151,899,000142,756,000217,912,000317,669,000
-----3,071,00016,000169,000

Key Facts

Industry

Biotechnology

Sector

Healthcare

Headquarters

Plymouth Meeting, PA, US

CEO

Dr. Jeffrey M. Dayno M.D.

Employees

200

About the Company

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.